-
Palobiofarma achieves “first patient first visit” in two key Phase II studies
Read more: Palobiofarma achieves “first patient first visit” in two key Phase II studiesPalobiofarma has recruited the first patient in the two key multicenter Phase II clinical studies. The studies will evaluate the preliminary efficacy of PBF-677 in Ulcerative Colitis patients and the efficacy of PBF-680 is mild to moderate asthmatics.
-
Palobiofarma advances it´s broad clinical pipeline
Read more: Palobiofarma advances it´s broad clinical pipelinePalobiofarma plans to start to key multicenter Phase II clinical studies the second quarter of 2018. The studies will evaluate the preliminary efficacy of PBF-677 in Ulcerative Colitis patients and the efficacy of PBF-680 is mild to moderate asthmatics.
-
FDA grants Palobiofarma approval to start second anti-cancer study in USA
Read more: FDA grants Palobiofarma approval to start second anti-cancer study in USAPalobiofarma has received FDA approval to initiate a Phase I clinical trial with the novel adenosine A2b antagonist PBF-1129 in lung cancer patients. The trial will be conducted at Ohio State University Comprehensive Cancer Center, Ohio, USA.
-
Palobiofarma initiates clinical development of it´s novel dual PDE10/A2a antagonist in solid tumors
Read more: Palobiofarma initiates clinical development of it´s novel dual PDE10/A2a antagonist in solid tumorsPalobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors. The trial will be conducted at the Vall D Hebron Hospital, in…
